Michael Quirmbach, CordenPharma CEO

Two in­vestors team up for Cor­den­Phar­ma buy­out fol­low­ing mR­NA vac­cine suc­cess

In March, Cor­den­Phar­ma was list­ed among the phar­ma gi­ants picked by the Ger­man gov­ern­ment as re­cip­i­ents of more than $3 bil­lion to en­sure that the coun­try had enough pro­duc­tion ca­pac­i­ty to make Covid-19 vac­cines for fu­ture out­breaks. In­vestors at As­torg and ICIG seemed to have liked what they saw and an­nounced Mon­day that the pri­vate eq­ui­ty firms have teamed up to ac­quire the CD­MO.

With the ac­qui­si­tion, As­torg and ICIG will get a rapid­ly grow­ing com­pa­ny thanks to its in­volve­ment in the mR­NA vac­cine game. Cor­den has al­so po­si­tioned it­self as a key play­er in the world of pep­tides and high-po­ten­cy com­pounds for on­col­o­gy. It picked up Vi­for Phar­ma’s drug man­u­fac­tur­ing wing in De­cem­ber 2021, land­ing op­er­a­tions in Fri­bourg and Et­tin­gen, Switzer­land, and Lis­bon, Por­tu­gal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA